Dominique Costantini

This inventor holds 11 USPTO granted patents and 5 published patent applications, plus 6 CIPO patents and 5 EPO patents. Top assignees: Bioalliance Pharma, Ose Immunotherapeutics, Bioalliance Pharma Sa. Active years: 2005-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dominique Costantini. Retrieved from https://idiyas.com/inventor/dominique-costantini

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 5)

% Patents Active = 81.8

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 9)

Average Co-Inventor Count = 1.6

ph-index = 3

Forward Citations = 67(Granted Patents)

Company Filing History:

Ose Immunotherapeutics

patents

2 out of 5

Bioalliance Pharma Sa

patents

4. 1 out of 1

Orphan Synergy Europe-Pharma

patent

Years Active: 2005-2023

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11696936 - Treatment of cancer (2023-07-11),

2. 11191820 - Method for inducing early T memory response with short peptides anti-tumor vaccine (2021-12-07),

3. 10434157 - Therapeutic multi-peptides T specific immune therapy for treatment of brain metastasis (2019-10-08),

4. 9301955 - Tritoqualine for use in the treatment of cystic fibrosis (2016-04-05),

5. 8791127 - Mucosal bioadhesive slow release carrier for delivering active principles (2014-07-29),

6. 8747896 - Mucosal bioadhesive slow release carrier for delivering active principles (2014-06-10),

7. 8592434 - Mucoadhesive buccal tablets for the treatment of orofacial herpes (2013-11-26),

8. 8518442 - Prolonged release bioadhesive therapeutic systems (2013-08-27),

9. 8211466 - Mucosal bioadhesive slow release carrier for delivering active principles (2012-07-03),

10. 7651698 - Prolonged release bioadhesive therapeutic systems (2010-01-26),

11. 6916485 - Prolonged release bioadhesive therapeutic systems (2005-07-12),

Title: Innovations in Cancer Treatment by Dominique Costantini

Introduction

Dominique Costantini is a prominent inventor based in Paris, France. He has made significant contributions to the field of cancer treatment, holding a total of 11 patents. His work focuses on innovative therapies that enhance patient outcomes, particularly for those undergoing immune checkpoint inhibitor treatments.

Latest Patents

Among his latest patents, Costantini has developed a treatment for cancer that involves a composition of CTL peptides. This invention aims to improve the treatment of cancer patients who have previously received immune checkpoint inhibitors. Another notable patent is a method for inducing an early T memory response using short peptides in an anti-tumor vaccine. This therapeutic approach is designed for HLA-A2 positive patients and includes a priming period with multiple administrations of the therapeutic peptide to stimulate a memory T cell response.

Career Highlights

Throughout his career, Costantini has worked with several notable companies in the pharmaceutical and biotechnology sectors. He has been associated with Bioalliance Pharma and Ose Immunotherapeutics, where he has contributed to the development of innovative cancer therapies.

Collaborations

Costantini has collaborated with various professionals in his field, including Caroline Lemarchand and Jean-Marc Aiache. These collaborations have furthered his research and development efforts in cancer treatment.

Conclusion

Dominique Costantini's work exemplifies the impact of innovation in cancer treatment. His patents and collaborations reflect a commitment to advancing therapeutic options for patients. His contributions are vital in the ongoing fight against cancer.

Profile summary based on public USPTO records.